Sign In
Buy VNRX
$2.08
-0.240 (-10.34%)
At Close: Jun 03, 2026
VolitionRx Limited prices major public offering to fund research and product development
01:31pm, Thursday, 01'st Jun 2023
VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million. The epigenetics company plans to offer 13 million shares at $1.
VolitionRx reports cash and cash equivalents of $10M at 1Q-end
08:17am, Thursday, 11'th May 2023
VolitionRx (NYSE-A:VNRX) Limited said it had cash and cash equivalents of around $10 million as of March 31, 2023, as it announced financial results and a business update for the first quarter. The co
VolitionRx posts 240% rise in 2022 revenue; outlines upcoming milestones
07:46am, Thursday, 16'th Mar 2023
VolitionRx Limited (NYSE-A:VNRX) has reported a sharp rise in annual revenue as it ‘shifts gears' towards its goal of becoming a commercial company with products. The company, which is developin
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
08:00am, Friday, 10'th Mar 2023
Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev.
VolitionRx reveals pricing of its $7.5M public equity offering
09:33am, Friday, 17'th Feb 2023
VolitionRx (NYSE-A:VNRX) Limited announced that it has priced its underwritten public offering of 4.3 million company common shares at $1.75 per share, with expected gross proceeds to Volition of $
Why Is VolitionRX (VNRX) Stock Down 17% Today?
09:08am, Friday, 17'th Feb 2023
VolitionRX (NYSEMKT: VNRX ) stock is taking a beating on Friday after the company revealed a proposed public offering for its shares. The big news here is VolitionRX planning a public offering of it V
VolitionRx says Nu.Q Vet Cancer Test now available for pre-order at the point-of-care through Heska Corporation
08:51am, Thursday, 16'th Feb 2023
VolitionRx (NYSE-A:VNRX) has announced its Nu.Q Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation. The Henderson, Nevada-based multi-nat
VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory network
09:23am, Thursday, 12'th Jan 2023
VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory network in the US. The Henderson, Nevada-based multi-na
VolitionRx highlights 2022 achievements as it advances to commercial operations
06:46am, Monday, 09'th Jan 2023
VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and development to one with commercial operations. Henderso
Penny Stocks To Buy: 6 Insider Picks Before 2023
12:24pm, Wednesday, 21'st Dec 2022
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny
3 Top Penny Stocks To Buy According To Insiders Before 2023
12:18pm, Tuesday, 20'th Dec 2022
Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Informat
VolitionRx Limited (VNRX) Q3 2022 Earnings Call Transcript
01:22pm, Tuesday, 15'th Nov 2022
VolitionRx Limited (NYSE:VNRX ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - Founder, Group CEO Tom Butera - CEO, Volition Ve
VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening company
09:14am, Tuesday, 15'th Nov 2022
VolitionRx (NYSE-A:VNRX) said it ended third-quarter 2022 with US$16.4 million in cash and cash equivalents, thanks to careful management of expenditures with net cash used in operating activities ave
VolitionRx teams up with leading French veterinary group to assess potential of cancer screening technology
09:18am, Monday, 14'th Nov 2022
VolitionRx (NYSE-A:VNRX) Limited said it will work with a renowned French veterinary referral clinic to further assess the potential of its cancer screening technology in dogs and cats. A non-interven
VolitionRX inks global agreement to provide Nu.Q cancer detection test to veterinarians
10:00am, Thursday, 20'th Oct 2022
VolitionRx (NYSE-A:VNRX) said it has signed a global agreement with a market leader in pet healthcare to supply its Nu.Q Vet Cancer Test to veterinarians. According to VolitionRx (NYSE-A:VNRX), there
